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Abstract
The past decade has seen extraordinary increase in worldwide availability of and access to several large multiple sclerosis (MS)
databases and registries. MS registries represent powerful tools to provide meaningful information on the burden, natural history,
and long-term safety and effectiveness of treatments. Moreover, patients, physicians, industry, and policy makers have an active
interest in real-world observational studies based on register data, as they have the potential to answer the questions that are most
relevant to daily treatment decision-making. In 2014, the Italian MS Foundation, in collaboration with the Italian MS clinical
centers, promoted and funded the creation of the ItalianMSRegister, a project in continuity with the existing ItalianMSDatabase
Network set up from 2001.Main objective of the ItalianMSRegister is to create an organized multicenter structure to collect data
of all MS patients for better defining the disease epidemiology, improving quality of care, and promoting research projects in
high-priority areas. The aim of this article is to present the current framework and network of the ItalianMS register, including the
methodology used to improve the quality of data collection and to facilitate the exchange of data and the collaboration among
national and international groups.
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Introduction
Disease registries are well recognized as powerful tools to pro-
vide meaningful information on the burden, natural history, and
long-term safety and effectiveness of treatments in the Breal-life^
population of patients with chronic diseases [1, 2]. Registries can
successfully operate by the creation of a network of reference
centers and a good collaborative feeling either from clinicians or
from patients to assure a high-quality data collection. Moreover,
registries need important economical investment to build the
structure of the database and the software, disseminate the tool
among centers, and maintain and monitor its appropriate use.
Registries are receiving increased attention for their potential role
in policy-making or decision-making processes for the
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development of appropriatemodel of care [3]. In recent years, the
worldwide availability of several large multiple sclerosis (MS)
databases [4]—combinedwith a growing ability to collect, share,
and analyze large amounts of data—are enabling the conduction
of real-world observational studies aimed to identify MS predic-
tionmodels for poor outcome and treatment response/failure, and
to evaluate comparative and long-term effectiveness and safety
of disease-modifying treatments in current use2, issues that can-
not be addressed by RCTs. Data collected through registries
should be used in prioritizing research and healthcare questions,
to focus resources on these high-priority areas would likely ac-
celerate progress in MS and to better leverage limited resources.
MS clinical data sharing initiative has a longstanding tra-
dition in Italy. In 2000, the Italian collection of MS clinical
data started at different Italian MS centers in the framework of
the Italian Multiple Sclerosis Database Network (MSDN) [5,
6]. This network used the iMed© software’s system, a clinical
database where more than 500 variables were collected [7].
Within this frame and in line with the International MS
research strategic agenda, since 2013, the Italian MS Society
representing people with MS (Associazione Italiana Sclerosi
Multipla—AISM) together with its foundation (Fondazione
Italiana Sclerosi Multipla—FISM) have been engaged in pro-
moting and funding data sharing initiatives. In 2014, FISM, in
collaboration with the Italian MS clinical centers, promoted
and funded the creation of the Italian MS Register, a project in
continuity with the existingMSDN-iMed© software’s clinical
database collection.
One of the first expressed purposes of Italian MS Register
is to create an organized multicenter structure to collect data of
all MS patients (a near population-level) followed in the larger
number of Italian MS centers.
The Italian MS Register aims to address high-priority areas
pertaining to
– public healthcare area: quality of care, health optimization
such as economical optimization, social and welfare in-
formation, access to healthcare treatments and healthcare
services
– research area: epidemiology, rare MS disease forms such
as, primary progressive (PP) MS, pediatric MS as well as
early and preclinical/subclinical disease stages represent-
ed by clinically isolated syndromes (CIS) and radiologi-
cally isolated syndromes (RIS), treatment optimization
such as prognostic factors and predictive models of dis-
ease course, adherence to treatments, treatment efficacy,
and safety.
The aim of this article is to present the current framework
and network of the Italian MS register, including the method
of work used to improve the quality of data collection and to
facilitate the exchange of data and the collaboration among
national and international groups.
Framework and network of the Italian MS
register
After completing preparatory phase, the Italian MS Register
officially started in January 2015. It is fully financed by FISM
and AISM, the MS national charity in Italy.
Governance
The governance of the ItalianMSRegister includes an Executive
Committee (chaired by AISM and University of Bari) with the
administrative and organizational role and a Scientific
Committee which oversees the scientific initiatives, promotes
specific strategic projects, and approves requests of access to
centralized data for further research projects. Scientific
Committee includes clinicians, methodologists, representatives
of MS centers, and of the Italian Neurological Society (SIN).
Technical and Administrative Infrastructure (TAI) is coor-
d ina ted by FISM accord ingly wi th a Technica l
Methodological Structure (TMS) based at IRCCS Istituto
Ricerche Farmacologiche Mario Negri-Coresearch.
In order to increase the quality of the data collected, a group
of 12 research assistants has been ad hoc trained for the project
with the objective to foster the collection of good quality data
in the Italian MS centers. Each assistant was allocated to one
or more centers (depending of the size of the MS center).
Research assistants monthly report the activity to the TMS,
and at least three/times year, they are involved in meeting to
discuss data collected. To meet the strategic priorities of the
Italian MS Register, relevant stakeholders, including indus-
tries, are engaged through advisory forum.
Through the website of the AISM, each participating center
can propose research projects addressing one of the high-
priority areas of the register. All the projects are discussed
by Scientific Committee before their implementation.
Ethics committee
The Italian MS register was approved by the Ethics
Committee of the University of Bari (Italy) as coordinator
center and the local ethics committee of all participant centers.
Each individual with a diagnosis of MS enrolled is required to
sign a written informed consensus to enter into the register.
Since in some of the participant centers data were collected
before the starting of the Italian MS Register (through iMed©
or other data-entry), according to the local laws and regula-
tions, data collected retrospectively can be also included with-
out informed consent.
MS centers
The medical assistance to MS patients in Italy is mainly
delivered by 236 qualified MS centers. The ambition of
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the Italian Register is to completely represent the MS
reality in Italy, so all the 236 Italian MS centers have
been contacted by AISM/FISM in order to explore their
willingness to participate to the Register project. Of
these, 141 (60%) declared the willingness to participate,
47 of them were already using the iMed© and were
asked to reverse their data in the new Register. The re-
maining MS centers were warmly encouraged to join in
the Register. The centers were required to include all the
MS cases in the Register, to transfer a standardized set of
data using local or central database, and to inform people
with MS about the Register. Participation in Italian MS
Register is voluntary both from the neurologist’s and the
patient’s side.
Data collection
The Scientific Committee agreed, by consensus, on a
compulsory common minimum dataset (MDS) consisting
of selected information according to the principles of
relevance to ensure the collection of sufficient data for
the clinical characterization of the single patient. The list
of the mandatory variables of interest, identified on the
basis of the existing guidelines and the recommendations
of the Scientific Committee, ensures
– participation of a large and representative number of centers
– easy and simple data collection
– ability to each center to achieve maximum completeness
and quality of data
– possible development of linkage procedures with regional
information flows of health administrative data (hospital
discharges, prescription drugs, ticket exemptions, register
of patients, outpatient specialist)
This MDS may be completed with an extension to optional
information already available in the iMed© computerized
medical folder [8, 9] (Table 1).
During its first years, the Italian MS Register was
based on a client–server solution, thus requiring hard-
ware, software installed on each computer (iMed© soft-
ware’s), and local IT support. At the end of 2016, it has
been decided that the Italian MS Register should go
web-based to also facilitate the interface with other na-
tional and international databases. This improvement of
data collection was implemented from 2017. A data col-
l e c t i on webs i t e i s now ava i l ab l e a t : h t t p s : / /
registroitalianosm.it/ where each center can enter the
data through a personalized password. Only cases with
MDS properly completed are accepted in the database. It
is noteworthy that in the Italian MS register, it is
possible to check the presence of a unique valid code
identifier, through the patient encrypted fiscal code, in
order to overcome one of the main issues of large
population registers that is the inclusion of the same
patient by two or more MS centers where the patient
himself had turned to their own care pathway.
Table 1 Simplified description of
the information collected by the
Italian MS Register with
indications of the mandatory
variables included in the MDS (in
bold) and the optional variables
(in italic). A detailed description
of the MDS variables is reported
in Appendix 1
Section Sub-Section Description
Baseline Clinical center Identification
Patient Identification and encryption of personal data
State of Life
Record creation date
Onset MS Date, symptoms, course (including RIS)
Diagnosis Date, Mc Donald Criteria 2010 and 2017 [8, 9]
Follow-up (FU) Visits Date, EDSS, course
Relapses Date, duration, functional systems involved, severity,
recovery, steroid treatment
Treatments Start date, end date, dosage, administration routes, disease
modifying or symptomatic therapies, discontinuation
cause (if applicable)
Adverse events Reporting severe adverse events and adverse events
(using MedDRA coding system)
Paraclinical tests Magnetic Resonance
Imaging
Date, CNS region, presence and number of T2, T1 and,
T1 Gd + lesions, McDonald’s Criteria (2017) for
space and time dissemination
Cerebrospinal fluid Date, routine, oligoclonal bands (presence/absence)
Evoked potentials Date, visual evoked potentials(VEP), upper and lower
somatosensory and motor evoked potentials (SEP and MEP),
brainstem auditory evoked potentials (BAEP)
Laboratory tests Date, routine, hematologic, virological, immunological, thyroid
function
Clinical events History Family history, pregnancies, comorbidities
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Data monitoring
Data are centrally monitored in order to guarantee a
high quality of information collected. Centers are peri-
odically contacted with ad hoc reports with queries on
the missing data or inconsistencies among the variables
collected.
Several quality control tools have been implemented
in order to increase the quality and generalizability of
data collected. Every 2/3 months per year, all the centers
are reached with a report regarding all the data collected
and a tailored report regarding each center. Quality con-
trols regard
– dates: presence/absence, completeness, anomalies and
consistency among all the data collected in the dataset
– completeness: overall evaluation of the completeness lev-
el of the variables included
– accuracy: proportion of variables with value correspond-
ing to their range
– consistency: congruency with other variables
Moreover, a set of seven performance indicators has been
identified and adopted with the aim to improve the quality, com-
pleteness of the survey, timeliness, generalization, and represen-
tativeness of the collected data (Table 2). For each examined
indicator or domain each participating center was awarded with
Table 2 Performance indicators
Score Optimal reference requirement Requirement calculation mode Assessment of the data quality
score (quality metrics)
Update
Center adherence to periodic
central database update
Participating centers are
required to upload data
to the central server every
6 months
Interval between the update
report date and the last
upload date
Within 6 months 5 points
> 6 months and ≤ 1 year 4
points
> 1 year and ≤ 2 years 3
points
> 2 years and ≤ 3 years 2
points
Over 3 years: 1 point
N. Patients-year
Sample size by center
Number of patients-year in the
top quintile
The number of patients per
year is calculated as the sum
of the follow-up years* of
each patient
*Interval in years between last
and first visit date recorded
Attribution based on
quintile distribution:
Within V quintile 5 points
Within IV quintile 4 points
Within III quintile 3 points
Within II quintile 2 points
Within I quintile 1 point
Patients with FUP ≥ 5 years
Sample size by center with prospective
clinical follow-up ≥ 5 years
% of patients with follow-up
≥ 5 years per center > 80%.
% of patients with follow-up
≥ 5 years per center
> 80% and ≤ 100% 5 points
> 60% and ≤ 80% 4 points
> 40% and ≤ 60% 3 points
> 20% and ≤ 40% 2 points
> 0% and ≤ 20% 1 point
Active patients
Patients in active status, i.e. at least
one visit and/or contact with the
center in the last two years
% of patients in active status
per center > 80%
% of patients in active status
per center
> 80% and ≤ 100% 5 points
> 60% and ≤ 80% 4 points
> 40% and ≤ 60% 3 points
> 20% and ≤ 40% 2 points
> 0% and ≤ 20% 1 point
VISIT every 6 months
Semi-annual visit rates
At least one visit every 6 months
in the follow-up period in
>80% of patients in each
center
% of patients with at least one
visit every 6 months in the
follow-up period for center
> 80% and ≤ 100% 5 points
> 60% and ≤ 80% 4 points
> 40% and ≤ 60% 3 points
> 20% and ≤ 40% 2 points
> 0% and ≤ 20% 1 point
EDSS every 6 months
Semi-annual EDSS assessment rates
At least one EDSS assessment
every 6 months in the
follow-up period
in > 80% of patients in each
center
% of patients with at least one
EDSS assessment every
6 months in the follow-up period
for center
> 80% and ≤ 100% 5 points
> 60% and ≤ 80% 4 points
> 40% and ≤ 60% 3 points
> 20% and ≤ 40% 2 points
> 0% and ≤ 20% 1 point
I° visit within I°year from onset
First visit within 1 year of the disease onset
At least one visit within one year
of the disease onset in >80% of
patients in each center
% of patients with at least one visit
within 1 year of the disease
onset for center
> 80% and ≤ 100% 5 points
> 60% and ≤ 80% 4 points
> 40% and ≤ 60% 3 points
> 20% and ≤ 40% 2 points
> 0% and ≤ 20% 1 point
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a score of 5 for the highest performance, while lower scores of 4
to 1 were attributed for progressively lower performance.
State-of-the art of the Italian MS register
MS centers
As reported in Fig. 1, 140 out of 236 contacted centers
(60%) declared the willingness to participate (last update
May 2018), and 103 completed their ethics committee
process for approval and are ready to participate to the
data collection. On May 2018, 72 MS centers effectively
contributed uploading data. The geographic distribution of
the centers is reported in Fig. 1.
Sample
The increasing temporal trends of the total cohort and
sub-cohorts with different follow-up duration (≥ 2.0, 5.0,
and 10 years) by May 2018 are reported in Fig. 2. The
same patient was registered in two or more sites in
6.1% of cases.
The data counts of the mandatory variables of 44,636 peo-
ple with MS included in the Register by May 2018 are sum-
marized in Table 3.
Consistency, completeness, and quality control
of data
Twenty-eight variables included in the MDS were selected to
evaluate the level of completeness. The percentage of com-
pleteness of the examined variables ranged between 30% (du-
ration in days of relapse) and 100% (for 10 of the 28 variables)
(Appendix 3).
An example of the quality control for the accuracy
and consistency of event dates (presence/absence and/or
anomalies among dates) is reported in Appendix 4. The
range of the accuracy and consistency was between
Region 140 centers 72 centers
Piemonte 11 6
Valle D'Aosta 1 0
Liguria 9 6
Lombardia 24 19
Trentino Alto Adige 0 0
Veneto 7 1
Friuli Venezia Giulia 1 0
Emilia Romagna 10 5
Toscana 15 1
Umbria 3 1
Marche 4 0
Lazio 14 9
Sardegna 4 2
Abruzzo 3 3
Molise 1 1
Puglia 9 5
Campania 9 6
Basilicata 2 0
Calabria 3 2
Sicilia 10 5
Fig. 1 Distribution of the 140
centers participants (black circle)
to Italian MS Register and of 72
centers (white circle) with actual
data transfer to the central
database
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96% (Date First Visit at the center) and 100% (for 9 of
15 variables).
Finally, the graphic representation of seven performance
indicators is reported in Fig. 3. Every 6 months, each partici-
pating center receives a report where data and performance
indicators of its own center are benchmarked with the whole
sample: in this way, each center can assess the most critical
performances and the level of improvement with time.
Research activity
A standardized process for applications of research project has
been developed. The applications are submitted through
https://www.aism.it/bandiregistro website after registration of
the project manager. Firstly, the feasibility of proposals (i.e.,
variables availability, completeness of data, size of the sample,
etc.) is assessed by TMS. Then, the members of the Scientific
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(Appendix 2 data in detail)
Table 3 Characteristics of 44,636
MS people with MS enrolled in
the Italian register
n = (%) Mean ± SD in years
Female 32,296 (67)
Age at onset (years) 30.5 ± 10.5
Delay between diagnosis and MS onset (years) 3.5 ± 5.8
Disease course at the last visit
Missing
Clinically Isolated syndrome
Relapsing-remitting
Secondary progressive
Primary progressive w or w/o relapses
828 (1.7)
2711 (5.6)
35,619 (74.0)
6115 (12.7)
2879 (6.0)
Number of visits per patient 13.4 ± 14.8
Number of registered DMD prescriptions 107,539
Number of registered relapses 160,419
Number of registered EDSS 570,640
Number of registered EDSS per patient 11.8 ± 13.6
Number of registered MRI 314,994
Number of registered MRI per patient 6.5 ± 7.1
160 Neurol Sci (2019) 40:155–165
Committee assess the proposals according to scientific quality,
value of the project, and alignment with priority areas of the
Register. Up to now, 14 research projects addressing one of
the high-priority areas of the Register have been proposed and
discussed by the Scientific Committee. The 12 approved pro-
jects cover the following research areas: epidemiology; prog-
nostic factors, and predictive models of disease course: adher-
ence, efficacy, and safety of the treatments.
Discussion
Patient registries gather valuable long-term patients’ informa-
tion from the real world which are useful to a wide range of
purposes: to better define the disease epidemiology within
specific geographic areas, understand the social and economic
impact of a disease; to provide the national regulatory author-
ities findings to make relevant decisions about focused
healthcare programs improving quality of healthcare; to im-
prove the care of MS patients; to provide updated information
on the evolution of MS in large cohorts of patients; and to
better evaluate the impact of DMTs in real life.
Concerning MS, some large-scale national and internation-
al registries and databases are currently in use with different
aims and designs [4, 10–17].
Italy is an area with medium-high prevalence ofMS, which
is estimated from 122 to 232 cases/100,000 in the mainland
and Sicily and from 280 to 317 cases/100,000 in Sardinia.
Applying an extrapolation to the Italian population in 2015,
about 110,000 MS patients are estimated in Italy [18].
In 2000, the Italian collection of MS clinical data started at
different Italian MS centers in the framework of MSDN [5, 6]
allowing the production of a number of scientific research
papers [19–25]. In 2014 FISM, in collaboration with the
Italian MS clinical centers, promoted the creation of the first
Italian MS Register.
In light of a practical guidance in setting up patient registries
[1], the Italian Register answers four main expectancies: (1) it
allows to collect reliable data for monitoring and evaluating
patient care, and to promote research projects (the Why—
mission and goals); (2) it has a clear and functional governance
structure that aligns the objectives of the register and agrees
with stakeholders (the Who—stakeholders and funding); (3) it
can easily collect specific data by means of a minimum data set
which reliability and validity has been carefully verified, thanks
to a sound network of Italian MS centers (the What—type and
content); (4) patients are well identified and recruited by cen-
ters with proven expertise in the field of MS, whose data are
protected, handled, and analyzed by a technical structure with
proven expertise in the field data management (the How—
identification and recruitment of patients, data handling).
The mission of the Italian Register project is not limited to
assure quality healthcare for patients with MS but also to
promote research projects addressing high-priority issues. At
present, 12 research projects are ongoing using the data col-
lected through the register.
With reference to a recent workshop on MS patient regis-
tries, we think that the so conceived Italian Register is already
responding to the main recommendations expressed by the
experts [25]. We detail below the seven recommendations,
how we currently deal with them, and what we aim to do to
improve their managing and development.
Recommendation 1 (Create a federated network of co-
horts). Our Italian MS Register is based on an already existing
network of MS centers. Anyway, 140 out of the 236 Italian
MS centers agreed to join in the Register project; thus, at the
0
1
2
3
4
5
Score_UPDATE
Score_N_Pts_year
Score_Pts_FUP≥5years
Score_Pts_acveScore_VISITE_6mm
Score_EDSS_6mm
Score_I°visit_within_I°yr
Center Code   - Update dd/mm/yyyy
Low Score High Score
Fig. 3 Quality of data collected. Legend (see also Table 2 for more
details). Score_UPDATE means adherence to periodic central database
update; Score_N._Pts_year means sample size by center; Score:_Pts_
with FUP ≥ 5 years means sample size by center with prospective clinical
follow-up ≥5 years; Score:_active Pts means patients in active status, i.e.,
at least one visit and/or contact with the center in the last 2 years; Score:_
VISITevery 6 months means semi-annual visit rates; Score:_EDSS every
6 months means semi-annual EDSS assessment rates; Score:_I°visit_
within_I° yr from onset means first visit within 2 year of the disease onset.
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present, the Italian Register contains the records of about
50,000 MS patients, which is 40% of the expected coverage
of Italian MS population. MS centers that did not contribute to
the initial phase of data collection and revision are now invited
to take part into the initiative to ensure the full coverage of the
Italian MS population.
Recommendation 2 (Standardize data collection and man-
agement). We have defined a set of MDS required to include
for each patient to ensure the collection of sufficient data for
their characterization. MDS allows us to record data in a stan-
dardized way. The support of research assistants, trained ad
hoc, improves the management of data and their quality. In the
future, the activity of research assistants should be strength-
ened and extended to the majority of MS centers, in order to
enrich the database not only quantitatively but also
qualitatively.
Recommendation 3 (Identify and prioritize research ques-
tions). Our Scientific Committee has identified research ques-
tions, giving them different priorities. The topics on which
researches will be focused might change in future, according
to the debate with MS centers, scientific societies, health au-
thorities, and stakeholders.
Recommendation 4 (encourage collection of physician-
and patient-reported outcomes). We will encourage, through
scientific societies and media tools, people involved in MS
management to join in the Italian Register project.
Neurologists could be further encouraged by the prospective
to make use of the register network to exploit researches ad-
dressing one of the high-priority areas of the Register.
Recommendation 5 (encourage technological innovation).
Our Register already employs an ad hoc database. In a short
time, specific additional database (for pediatric MS, pregnan-
cy, MRI) will be available, as well as a dedicated Internet
platform to facilitate data inclusion and transmission.
Recommendation 6 (develop a universal informed consent
process).We have defined an informed consensus that must be
signed to enter in the Italian Register. Anyway, given the wide
differences among the laws that rule ethical issues in different
nations, to get to informed consent universally shared is quite
unrealistic.
Recommendation 7 (provide sustainable funding). The
Register needs important economical investments to be dis-
seminated and maintained. At the moment, the Register is
funded by FISM and other donors, including pharmaceutical
companies engaged through advisory forum.
For several research purposes, although cohort studies and
registries typically include considerable numbers of patients,
analyses are often limited by poor statistical power owing to
insufficient numbers of patients. This is true for many aspects
of real-world analysis.
As a consequence, in the past 10 years, a fruitful collabora-
tion betweenMSBase and some Italian centers was established:
individual MS centers (10/140), belonging to the MS Database
Network, and currently belonging to the Italian MS Registry,
shared, on annual or biannual basis, their data with theMSBase
Registry for collaborative scientific projects. Currently, since an
Italian MS Registry has been set up with new rules, the collab-
oration with MSBase, and other European registries will occur
through data sharing for specific and agreed projects. Individual
centers will remain free to collaborate with MSBase or other
registries for specific projects, but not by releasing data regu-
larly and independently of them, and they must notify their
participation in these projects to the Scientific Committee in
order to avoid overlap with projects already underway in the
Italian Registry. This new approach will extend collaborations,
keeping the identity of the Italian registry separate from that of
MSBase or other registries.
Over the past 3 years, representatives of five leading MS
registries (including the Italian, Danish and Swedish MS regis-
tries, French Observatoire Française de Sclérose en Plaque net-
work and the international MSBase) have been working togeth-
er to explore opportunities for data sharing, so called BigMS
Data group project. Combined, the five registries collect longi-
tudinal data on > 150,000 patients withMS. To date, the BigMS
Data group has identified and agreed on a minimal set of pa-
rameters and initiated three pilot projects with joint data.
These efforts need to overcome challenges of technical,
ethical, legal, and political nature, but over long term, they
are hoped to be of significance. The key findings in interna-
tional registries should be also utilized in conjunction with
data from clinical trials to optimize treatment and improve
long-term outcomes.
In the next future, it would be desirable a larger use of MS
disease registries for the post-marketing drug safety assessment
(i.e., post-approval Safety—PASS- project recently proposed
by EMA). Indeed, large disease registries, unlike drug regis-
tries, can include information not only on products or proce-
dures of interest but also on similar patients who receive other
treatments, other procedures, or no treatment for the same clin-
ical indications allowing a better evaluation of event rates, con-
sequences of long-term use, and/or effects of various combina-
tions and sequencing of treatments. Moreover, the use of dis-
ease registries may provide a better understanding of the effects
of comorbidity on effectiveness and safety of DMTs.
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